Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2024 09:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 03, 2024 09:10 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Reports 2023 Results; Provides Business Update
March 28, 2024 08:30 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
February 21, 2023 06:06 ET | Source: JOWIN

Jowin, the Apple in Korea’s cancer treatment, expands their business globally

Korea's innovative venture company Jowin declares its expansion into the global cancer care market through the establishment of a global telemedicine platform.A telemedicine platform for overseas...
June 07, 2022 07:22 ET | Source: MetasTx LLC

MetasTx LLC Raises Funds, Engages Manufacturing Partner, And Advances Phase One Development

BASKING RIDGE, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- MetasTx LLC is driven to create novel therapeutics to treat and prevent metastasis of cancers. Harvey Homan, CEO and Co-Founder has...
June 03, 2019 16:05 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019

No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T cell populations similar...
June 03, 2019 09:05 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019

No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 ...